Synapse

← Lewis C. Cantley

Papers by Lewis C. Cantley

Page 3 · newest first

  1. Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancerInternational Journal of Cancer · 2019
  2. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitorsScience · 2019
  3. Structure–Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase InhibitorsACS Medicinal Chemistry Letters · 2019
  4. Targeting the PI5P4K lipid kinase family in cancer using novel covalent inhibitors2019
  5. PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancernpj Breast Cancer · 2019
  6. Tissue of Origin Dictates GOT1 Dependence and Confers Synthetic Lethality to Radiotherapy2019
  7. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutationBreast Cancer Research · 2019
  8. PIP4Ks Suppress Insulin Signaling through a Catalytic-Independent MechanismCell Reports · 2019
  9. Mapping Post-Translational Modifications of de Novo Purine Biosynthetic Enzymes: Implications for Pathway RegulationJournal of Proteome Research · 2019
  10. High-fructose corn syrup enhances intestinal tumor growth in miceScience · 2019
  11. Regulation of folate and methionine metabolism by multisite phosphorylation of human methylenetetrahydrofolate reductaseScientific Reports · 2019
  12. Dietary Fat and Sugar in Promoting Cancer Development and ProgressionAnnual Review of Cancer Biology · 2019
  13. Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistanceJournal of Lipid Research · 2019
  14. Rac-Mediated Macropinocytosis of Extracellular Protein Promotes Glucose Independence in Non-Small Cell Lung CancerCancers · 2019
  15. Toward a better understanding of folate metabolism in health and diseaseThe Journal of Experimental Medicine · 2018
  16. A Chemoproteomic Strategy for Direct and Proteome-Wide Covalent Inhibitor Target-Site IdentificationJournal of the American Chemical Society · 2018
  17. Phosphatidylinositol 3-Kinase, Growth Disorders, and CancerNew England Journal of Medicine · 2018
  18. The chromatin remodeler RSF1 controls centromeric histone modifications to coordinate chromosome segregationNature Communications · 2018
  19. PIP4Ks Suppress Insulin Signaling Through a Catalytic-Independent Mechanism2018
  20. Cancer metabolism gets physicalScience Translational Medicine · 2018
  21. Chromosomal instability drives metastasis through a cytosolic DNA responseNature · 2018
  22. Fenofibrate prevents skeletal muscle loss in mice with lung cancerProceedings of the National Academy of Sciences · 2018
  23. PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K α InhibitorsClinical Cancer Research · 2017
  24. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast CancerCancer Discovery · 2017
  25. Proteomic and Metabolomic Characterization of a Mammalian Cellular Transition from Quiescence to ProliferationCell Reports · 2017
  26. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85αProceedings of the National Academy of Sciences · 2017
  27. Phosphorylation of TXNIP by AKT Mediates Acute Influx of Glucose in Response to InsulinCell Reports · 2017
  28. Personalized In Vitro and In Vivo Cancer Models to Guide Precision MedicineCancer Discovery · 2017
  29. Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate ImmunityCancer Discovery · 2017
  30. PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase InhibitionCancer Discovery · 2017
  31. PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-NitrosylationMolecular Cell · 2017
  32. α-Ketothioamide Derivatives: A Promising Tool to Interrogate Phosphoglycerate Dehydrogenase (PHGDH)Journal of Medicinal Chemistry · 2017
  33. Obesity and Cancer Mechanisms: Cancer MetabolismJournal of Clinical Oncology · 2016
  34. Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survivalProceedings of the National Academy of Sciences · 2016
  35. Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletionProceedings of the National Academy of Sciences · 2016
  36. Deletion of the gene Pip4k2c , a novel phosphatidylinositol kinase, results in hyperactivation of the immune systemProceedings of the National Academy of Sciences · 2016
  37. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast CancerClinical Cancer Research · 2016
  38. A novel small-molecule inhibitor of 3-phosphoglycerate dehydrogenaseMolecular & Cellular Oncology · 2016
  39. Prioritization schema for immunotherapy clinical trials in glioblastomaOncoImmunology · 2016
  40. A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2Scientific Reports · 2016
  41. Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancersProceedings of the National Academy of Sciences · 2016
  42. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDHScience · 2015
  43. NRF2 regulates serine biosynthesis in non–small cell lung cancerNature Genetics · 2015
  44. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachoneCancer & Metabolism · 2015
  45. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic CharacteristicsCancer Discovery · 2015
  46. AACR Cancer Progress Report 2015Clinical Cancer Research · 2015
  47. PtdIns(3,4,5) P 3-Dependent Activation of the mTORC2 Kinase ComplexCancer Discovery · 2015
  48. PTEN loss is a context‐dependent outcome determinant in obese and non‐obese endometrioid endometrial cancer patientsMolecular Oncology · 2015
  49. Gain of Glucose-Independent Growth upon Metastasis of Breast Cancer Cells to the BrainCancer Research · 2014
  50. Vulnerabilities of PTEN – TP53 -Deficient Prostate Cancers to Compound PARP–PI3K InhibitionCancer Discovery · 2014